Results 81 to 90 of about 918 (92)
Some of the next articles are maybe not open access.
Cancer Biotherapy and Radiopharmaceuticals, 2007
One of the few treatment options for inoperable neuroendocrine tumors (NET) is peptide receptor radiotherapy with somatostatin analogs. In this study, we compared the dosimetric parameter uptake, half-life (kinetics), and mean absorbed organ and tumor doses of (177)Lu DOTA-NOC and (177)Lu DOTA-TATE.Ninety-five (95) post-therapeutic dosimetric ...
Christiane, Wehrmann +4 more
openaire +2 more sources
One of the few treatment options for inoperable neuroendocrine tumors (NET) is peptide receptor radiotherapy with somatostatin analogs. In this study, we compared the dosimetric parameter uptake, half-life (kinetics), and mean absorbed organ and tumor doses of (177)Lu DOTA-NOC and (177)Lu DOTA-TATE.Ninety-five (95) post-therapeutic dosimetric ...
Christiane, Wehrmann +4 more
openaire +2 more sources
Nuclear Medicine Communications
Objective 177 Lu-DOTA-TATE (LUTATHERA) is a crucial radiopharmaceutical in neuroendocrine tumor therapy, yet real-world long-term safety data across diverse populations remain limited.
Xinhua Wu +3 more
openaire +1 more source
Objective 177 Lu-DOTA-TATE (LUTATHERA) is a crucial radiopharmaceutical in neuroendocrine tumor therapy, yet real-world long-term safety data across diverse populations remain limited.
Xinhua Wu +3 more
openaire +1 more source
The Effectiveness of 177Lu-DOTA TATE in Radioiodine-Refractory Differentiated Thyroid Cancer
2020[No Abstract Available]
Nazari, A. +6 more
openaire +1 more source
PRRT 177Lu-DOTA-TATE in pancreatic neuroendocrine tumors - When to initiate?
Endocrine Abstracts, 2023Sara Franco +8 more
openaire +1 more source
Current radiopharmaceuticals, 2015
Patient dose of (177)Lu-DOTA-TATE, used for providing radiotherapeutic treatment to the patients suffering from cancers of neuroendocrine origin, could be prepared at the hospital radiopharmacy either 'in-situ' or by using freezedried kits. The objective of the present work is to formulate and evaluate a single vial freeze-dried DOTA-TATE kit, which is
Tapas, Das +4 more
openaire +1 more source
Patient dose of (177)Lu-DOTA-TATE, used for providing radiotherapeutic treatment to the patients suffering from cancers of neuroendocrine origin, could be prepared at the hospital radiopharmacy either 'in-situ' or by using freezedried kits. The objective of the present work is to formulate and evaluate a single vial freeze-dried DOTA-TATE kit, which is
Tapas, Das +4 more
openaire +1 more source
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2013
Aim of this study was to evaluate the effectiveness of non-carrier added (n. c. a.) [177Lu]DOTA-TATE in inoperable liver metastases, positive for sst2 receptor overexpression (verified by Octreoscan and confirmed by biopsy) due to neuroendocrine gastroenteropancreatic (GEP) tumors.
G S, Limouris +10 more
openaire +1 more source
Aim of this study was to evaluate the effectiveness of non-carrier added (n. c. a.) [177Lu]DOTA-TATE in inoperable liver metastases, positive for sst2 receptor overexpression (verified by Octreoscan and confirmed by biopsy) due to neuroendocrine gastroenteropancreatic (GEP) tumors.
G S, Limouris +10 more
openaire +1 more source
Revista Española de Medicina Nuclear e Imagen Molecular, 2023
Angela Leiva Montejo +8 more
openaire +1 more source
Angela Leiva Montejo +8 more
openaire +1 more source
NETTER-1 Studie zur 177Lu-DOTA-TATE Therapie bei fortgeschrittenen neuroendokrinen Tumoren
Der Radiologe, 2017openaire +1 more source
Does 177Lu-DOTA-TATE works in metastatic cardiac paraganglioma?
Endocrine AbstractsRegina Medeiros +3 more
openaire +1 more source